KR960705512A - 생체적합성 안과용 삽입체(biocompatible ocular implants) - Google Patents

생체적합성 안과용 삽입체(biocompatible ocular implants) Download PDF

Info

Publication number
KR960705512A
KR960705512A KR1019960702428A KR19960702428A KR960705512A KR 960705512 A KR960705512 A KR 960705512A KR 1019960702428 A KR1019960702428 A KR 1019960702428A KR 19960702428 A KR19960702428 A KR 19960702428A KR 960705512 A KR960705512 A KR 960705512A
Authority
KR
South Korea
Prior art keywords
agent
eye
site
biocompatible polymer
introducing
Prior art date
Application number
KR1019960702428A
Other languages
English (en)
Inventor
지. 웡 버어넌
코칭크 프랭크
Original Assignee
제리 비. 진
오쿨렉스 파마슈티컬즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 제리 비. 진, 오쿨렉스 파마슈티컬즈, 인코포레이티드 filed Critical 제리 비. 진
Publication of KR960705512A publication Critical patent/KR960705512A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F9/00—Methods or devices for treatment of the eyes; Devices for putting-in contact lenses; Devices to correct squinting; Apparatus to guide the blind; Protective devices for the eyes, carried on the body or in the hand
    • A61F9/0008—Introducing ophthalmic products into the ocular cavity or retaining products therein
    • A61F9/0017—Introducing ophthalmic products into the ocular cavity or retaining products therein implantable in, or in contact with, the eye, e.g. ocular inserts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts, ocular implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/18—Modification of implant surfaces in order to improve biocompatibility, cell growth, fixation of biomolecules, e.g. plasma treatment
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 치료를 위해 눈의 맥락막 상층 공간 또는 무혈관 영역 내로 도입시키기 위해 사용되는 활성제를 포함하는 삽입체에 관한 것이다. 약제의 투여도는 조절되고, 장기간 동안 유지되며, 투여 자리 이외의 상당한 농도의 실질적 부재를 보장한다.

Description

생체적합성 안과용 삽입체(BIOCOMPATIBLE OCULAR IMPLANTS)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

  1. 약리학적으로 허용될 수 있는 생체 적합성 중합체에 의해 캡슐화되는 약제, 약리학적 제제 및 박테리아 제제 중 하나 이상으로부터 선택된 제제로 이루어지고 연장된 기간동안 효과적인 용량의 상기 제제를 제공하는, 유리체와 무관한 자리로부터 이행할 수 없는 삽입체를 유리체와 무관한 자리 내에 도입시키는 것을 포함하는 안과 질환의 치료 방법.
  2. 제1항에 있어서, 상기 생체 적합성 중합체가 비-생분해성임을 특징으로 하는 방법.
  3. 제2항에 있어서, 상기 중합체가 폴리우레탄임을 특징으로 하는 방법.
  4. 제2항에 있어서, 상기 중합체가 에틸렌 비닐 에스테르 공중합체임을 특징으로 하는 방법.
  5. 제4항에 있어서, 상기 에틸렌 비닐 에스테르 공중합체가 에틸렌 비닐 아세티이트임을 특징으로 하는 방법.
  6. 제1항에 있어서, 상기 자리가 맥락막 상층 공간임을 특징으로 하는 방법.
  7. 제1항에 있어서, 상기 자리가 무혈관 영역임을 특징으로 하는 방법.
  8. 제7항에 있어서, 상기 무혈관 영역이 외과적으로 유도되는 무혈관 영역임을 특징으로 하는 방법.
  9. 약리학적으로 허용될 수 있는 생체 적합성 중합체에 의해 캡슐화되는 약제, 약리학적 제제 및 박테리아 제제 중 하나 이상으로부터 선택된 제제로 이루어지고 연장된 기간동안 효과적인 용량의 상기 제제를 제공하는, 눈의 편평부로부터 이행할 수 없는 삽입체를 눈의 편평부 내에 도입시키는 것을 포함하는 눈병의 치료 방법.
  10. 약제, 약리학적 제제 및 박테리아 제제 중 하나 이상으로부터 선택된 제1활성제 및 제2투과성 증강제(상기 제1 및 제2제제는 약리학적으로 혀용될 수 있는 생체 적합성 중합체에 의해 캡슐와됨)로 이루어지고, 연장된 기간 동안 효과적인 용량의 상기 제1제제를 제공하는, 눈의 편평부로부터 이행할 수 없는 삽입체를 눈의 편평부 내에 도입시키는 것을 눈병의 치료 방법.
  11. 제10항에 있어서, 상기 투과성 증강제가 미리스트산 이소프로필, 에탄올 또는 올레산 중 하나로부터 선택됨을 특징으로 하는 방법.
  12. 하나 이상의 항종양제 및 약리학적으로 허용될 수 있는 생체 적합성 중합체로 이루어진, 눈의 맥락막 상층 공간으로부터 이행할 수 없는 삽입체를 눈의 맥락막 상층 공간 내에 도입시키는 것을 포함하는 눈의 맥락막 종양의 치료 방법.
  13. 제12항에 있어서, 상기 삽입체가 0.5 내지 10㎜의 길이 및 폭치수, 및 0.25 내지 10㎜의 두께를 갖는 플라크임을 특징으로 하는 방법.
  14. 제13항에 있어서, 상기 항종양제가 케토트렉세이트, 빈크리스틴 또는 박테리아 제제임을 특징으로 하는 방법.
  15. 제14항에 있어서, 상기 박테리아 제제가 산-패스트 바실리 또는 C. parvum임을 특징으로 하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019960702428A 1993-11-15 1994-11-09 생체적합성 안과용 삽입체(biocompatible ocular implants) KR960705512A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/153,184 1993-11-15
US08/153,184 US5443505A (en) 1993-11-15 1993-11-15 Biocompatible ocular implants
PCT/US1994/012898 WO1995013765A1 (en) 1993-11-15 1994-11-09 Biocompatible ocular implants

Publications (1)

Publication Number Publication Date
KR960705512A true KR960705512A (ko) 1996-11-08

Family

ID=22546138

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960702428A KR960705512A (ko) 1993-11-15 1994-11-09 생체적합성 안과용 삽입체(biocompatible ocular implants)

Country Status (11)

Country Link
US (3) US5443505A (ko)
EP (1) EP0729324B1 (ko)
JP (1) JPH09505300A (ko)
KR (1) KR960705512A (ko)
CN (1) CN1139375A (ko)
AT (1) ATE274872T1 (ko)
AU (1) AU1092495A (ko)
DE (1) DE69433981T2 (ko)
ES (1) ES2231781T3 (ko)
TW (1) TW368411B (ko)
WO (1) WO1995013765A1 (ko)

Families Citing this family (544)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2290074T3 (es) 1993-07-19 2008-02-16 Angiotech Pharmaceuticals, Inc. Composiciones anti-angiogenicas que contienen taxol y un vehiculo no biodegradable y su uso.
US5716981A (en) * 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5620013A (en) * 1994-10-21 1997-04-15 American Cyanamid Company Method for destroying residual lens epithelial cells
US5869079A (en) * 1995-06-02 1999-02-09 Oculex Pharmaceuticals, Inc. Formulation for controlled release of drugs by combining hydrophilic and hydrophobic agents
US20060280774A1 (en) * 1995-06-02 2006-12-14 Allergan, Inc. Compositions and methods for treating glaucoma
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
US5904144A (en) * 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
US6063370A (en) * 1996-04-05 2000-05-16 The Board Of Trustees Of The University Of Illinois Macromolecular complexes for drug delivery
US5935599A (en) * 1996-10-28 1999-08-10 The Board Of Trustees Of The University Of Illinois Polymer-associated liposomes for drug delivery and method of manufacturing the same
WO1999007418A2 (en) * 1997-08-11 1999-02-18 Allergan Sales, Inc. Sterile bioerodible implant device with improved biocompatability and method
US6007578A (en) * 1997-10-08 1999-12-28 Ras Holding Corp Scleral prosthesis for treatment of presbyopia and other eye disorders
US6991650B2 (en) 1997-10-08 2006-01-31 Refocus Ocular, Inc. Scleral expansion device having duck bill
EP1174157B1 (en) 1998-04-27 2005-06-29 Surmodics Inc. Bioactive agent release coating
WO2000000106A1 (en) * 1998-06-29 2000-01-06 Rozakis George W Antioxidant intraocular lens
US6024719A (en) 1998-07-06 2000-02-15 Morris; Robert E Method and apparatus for performing surgery inside the human retina using fluidic internal limiting membrane (ILM) seperation (FILMS)
US6309374B1 (en) 1998-08-03 2001-10-30 Insite Vision Incorporated Injection apparatus and method of using same
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
FR2787991B1 (fr) * 1998-12-31 2001-05-25 Medicale De Prec S M P Sa Soc Dispositif pour traiter la presbytie ou autre affection oculaire
CA2358296A1 (en) * 1999-01-05 2000-07-13 Anthony P. Adamis Targeted transscleral controlled release drug delivery to the retina and choroid
US6113638A (en) * 1999-02-26 2000-09-05 Williams; Lytton A. Method and apparatus for intervertebral implant anchorage
US20040121014A1 (en) * 1999-03-22 2004-06-24 Control Delivery Systems, Inc. Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6217895B1 (en) * 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
CZ20013823A3 (cs) 1999-04-26 2002-03-13 Gmp Vision Solutions, Inc. Stentovací zařízení a metoda léčby glaukomu
US6699210B2 (en) * 1999-04-27 2004-03-02 The Arizona Board Of Regents Glaucoma shunt and a method of making and surgically implanting the same
WO2000074600A1 (en) 1999-06-07 2000-12-14 Ras Holding Corporation Improved scleral prosthesis for treatment of presbyopia and other eye disorders
US7008396B1 (en) 1999-09-03 2006-03-07 Restorvision, Inc. Ophthalmic device and method of manufacture and use
DE19947711B4 (de) * 1999-10-04 2004-02-12 Schrage, Norbert, Priv. Doz. Dr.med. Implantat zum Eisatz in der Glaukomtherapie
ES2231257T3 (es) 1999-10-21 2005-05-16 Alcon Inc. Dispositivo para la administracion de farmacos.
US7943162B2 (en) * 1999-10-21 2011-05-17 Alcon, Inc. Drug delivery device
US6416777B1 (en) * 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
EP1522289A3 (en) 1999-10-21 2008-01-23 Alcon, Inc Sub-tenon drug delivery
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
US6852688B2 (en) 2000-03-10 2005-02-08 University Of Florida Compositions for treating diabetic retinopathy and methods of using same
US20050277864A1 (en) * 2000-04-14 2005-12-15 David Haffner Injectable gel implant for glaucoma treatment
US20050049578A1 (en) * 2000-04-14 2005-03-03 Hosheng Tu Implantable ocular pump to reduce intraocular pressure
US7708711B2 (en) 2000-04-14 2010-05-04 Glaukos Corporation Ocular implant with therapeutic agents and methods thereof
US7867186B2 (en) 2002-04-08 2011-01-11 Glaukos Corporation Devices and methods for treatment of ocular disorders
US20040111050A1 (en) * 2000-04-14 2004-06-10 Gregory Smedley Implantable ocular pump to reduce intraocular pressure
US20020143284A1 (en) * 2001-04-03 2002-10-03 Hosheng Tu Drug-releasing trabecular implant for glaucoma treatment
US6638239B1 (en) * 2000-04-14 2003-10-28 Glaukos Corporation Apparatus and method for treating glaucoma
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
US6417237B1 (en) 2000-06-08 2002-07-09 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes and compositions containing the same
US6692759B1 (en) * 2000-06-28 2004-02-17 The Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
EP3167872B1 (en) 2000-07-05 2020-10-14 Allergan, Inc. Methods for treating inflammation-mediated conditions of the eye
US6726918B1 (en) 2000-07-05 2004-04-27 Oculex Pharmaceuticals, Inc. Methods for treating inflammation-mediated conditions of the eye
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
EP1992317B1 (en) 2000-08-30 2012-02-29 Johns Hopkins University Devices for intraocular drug delivery
AR031135A1 (es) 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
US20030082183A1 (en) * 2000-11-01 2003-05-01 Wheeler Larry A. Methods and compositions for treatment of ocular neovascularization and neural injury
WO2002058730A2 (en) * 2000-11-01 2002-08-01 Allergan, Inc. Compositions for treatment of ocular neovascularization
US6534693B2 (en) * 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
AU3649502A (en) 2000-11-29 2002-06-11 Oculex Pharm Inc Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor
WO2002055058A2 (en) 2001-01-09 2002-07-18 Microchips, Inc. Flexible microchip devices for ophthalmic and other applications
US6713081B2 (en) * 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
CA2683224C (en) 2001-04-07 2014-12-02 Glaukos Corporation System and methods thereof for treatment of ocular disorders
US7488303B1 (en) * 2002-09-21 2009-02-10 Glaukos Corporation Ocular implant with anchor and multiple openings
US6981958B1 (en) * 2001-05-02 2006-01-03 Glaukos Corporation Implant with pressure sensor for glaucoma treatment
US7431710B2 (en) 2002-04-08 2008-10-07 Glaukos Corporation Ocular implants with anchors and methods thereof
US7795218B2 (en) 2001-04-12 2010-09-14 Bioaxone Therapeutique Inc. ADP-ribosyl transferase fusion variant proteins
US20040022853A1 (en) * 2001-04-26 2004-02-05 Control Delivery Systems, Inc. Polymer-based, sustained release drug delivery system
US7678065B2 (en) 2001-05-02 2010-03-16 Glaukos Corporation Implant with intraocular pressure sensor for glaucoma treatment
WO2002089699A2 (en) 2001-05-03 2002-11-14 Glaukos Corporation Medical device and methods of use for glaucoma treatment
US7563255B2 (en) 2001-05-03 2009-07-21 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
US20060241750A1 (en) * 2001-05-22 2006-10-26 Ras Holding Corp Scleral expansion device having duck bill
DE60239868D1 (de) * 2001-06-12 2011-06-09 Univ Johns Hopkins Med Reservoirvorrichtung für die intraokulare arzneimittelabgabe
US7592016B2 (en) * 2001-06-28 2009-09-22 Regents Of The University Of California Methods for preparing and using implantable substance delivery devices
DE10133870A1 (de) * 2001-07-12 2003-02-06 Chris P Lohmann Ophthalmisches Mittel, Verwendung von EGF zur Behandlung von Dry Eye-Syndrom und Insert zur Verabreichung von EGF am Auge
DE60217679T2 (de) 2001-07-23 2007-10-25 Alcon Inc. Vorrichtung zur freisetzung eines ophthalmischen arzneimittels
JP4249611B2 (ja) * 2001-07-23 2009-04-02 アルコン，インコーポレイティド 眼薬剤送致装置
US8267995B2 (en) * 2001-08-03 2012-09-18 David Castillejos Method and intra sclera implant for treatment of glaucoma and presbyopia
US7331984B2 (en) 2001-08-28 2008-02-19 Glaukos Corporation Glaucoma stent for treating glaucoma and methods of use
US7195774B2 (en) * 2001-08-29 2007-03-27 Carvalho Ricardo Azevedo Ponte Implantable and sealable system for unidirectional delivery of therapeutic agents to tissues
GB0122318D0 (en) * 2001-09-14 2001-11-07 Novartis Ag Organic compounds
IN2014DN10834A (ko) * 2001-09-17 2015-09-04 Psivida Inc
DE60218336T2 (de) * 2001-10-30 2007-10-31 Eyeborn (Proprietary) Ltd., Brummeria Orbitalimplantat
FR2833493B1 (fr) * 2001-12-18 2005-09-23 Ioltechnologie Production Forme galenique solide et soluble pour l'administration occulaire de principes actifs et procede de fabrication d'un insert ophtalmique solide et soluble
US20030180294A1 (en) * 2002-02-22 2003-09-25 Devries Gerald W. Methods of extending corneal graft survival
US7186232B1 (en) 2002-03-07 2007-03-06 Glaukoa Corporation Fluid infusion methods for glaucoma treatment
CA2478772C (en) * 2002-03-11 2011-01-18 Alcon, Inc. Implantable drug delivery system
US7951155B2 (en) 2002-03-15 2011-05-31 Glaukos Corporation Combined treatment for cataract and glaucoma treatment
US20040147870A1 (en) * 2002-04-08 2004-07-29 Burns Thomas W. Glaucoma treatment kit
US9301875B2 (en) 2002-04-08 2016-04-05 Glaukos Corporation Ocular disorder treatment implants with multiple opening
US20040024345A1 (en) * 2002-04-19 2004-02-05 Morteza Gharib Glaucoma implant with valveless flow bias
WO2003092665A2 (en) * 2002-05-02 2003-11-13 Massachusetts Eye And Ear Infirmary Ocular drug delivery systems and use thereof
US8871241B2 (en) * 2002-05-07 2014-10-28 Psivida Us, Inc. Injectable sustained release delivery devices
WO2003094888A1 (en) * 2002-05-07 2003-11-20 Control Delivery Systems, Inc. Processes for forming a drug delivery device
US7097850B2 (en) 2002-06-18 2006-08-29 Surmodics, Inc. Bioactive agent release coating and controlled humidity method
AU2003244854A1 (en) * 2002-07-09 2004-01-23 Anglo-European College Of Chiropractic Ltd Method for imaging the relative motion of skeletal segments
US20070184089A1 (en) * 2002-07-15 2007-08-09 Alcon, Inc. Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
ES2295647T3 (es) * 2002-07-15 2008-04-16 Alcon, Inc. Composiciones de implante farmaceuticas lipofilas, no polimeras, para uso intraocular.
US20070027537A1 (en) * 2002-08-02 2007-02-01 David Castillejos Method and intra-sclera implant for treatment of glaucoma and presbyopia
WO2004026347A2 (en) * 2002-09-17 2004-04-01 Iscience Surgical Corporation Apparatus and method for surgical bypass of aqueous humor
CN1301692C (zh) 2002-09-18 2007-02-28 阿勒根公司 眼植入物导入的器械
US20050203542A1 (en) * 2002-09-18 2005-09-15 Allergan, Inc. Apparatus for delivery of ocular implants with reduced incidence of ocular adverse events
US6899717B2 (en) * 2002-09-18 2005-05-31 Allergan, Inc. Methods and apparatus for delivery of ocular implants
US7468065B2 (en) 2002-09-18 2008-12-23 Allergan, Inc. Apparatus for delivery of ocular implants
WO2004036182A2 (en) * 2002-10-17 2004-04-29 Control Delivery Systems, Inc. Methods for monitoring treatment of disease
US20040111144A1 (en) * 2002-12-06 2004-06-10 Lawin Laurie R. Barriers for polymeric coatings
PT1585743E (pt) * 2002-12-19 2007-07-12 Pfizer Compostos de 2- (1h-indazol-6-ilamin)-benzamida como inibidores de proteína-cinases úteis para o tratamento de doenças aftálmicas.
US20040137068A1 (en) * 2002-12-20 2004-07-15 Rajiv Bhushan Ophthalmic formulation for the prevention and treatment of adverse ocular conditions, particularly those associated with the aging eye
US20060177430A1 (en) * 2002-12-20 2006-08-10 Chakshu Research Inc Treatment of ocular disorders with ophthalmic formulations containing methylsulfonylmethane as a transport enhancer
US20060166879A1 (en) * 2002-12-20 2006-07-27 Chakshu Research Inc Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
US20060172972A1 (en) * 2002-12-20 2006-08-03 Chakshu Research Inc Formulation and method for administration of ophthalmologically active agents
US8185209B2 (en) * 2003-01-03 2012-05-22 Board Of Trustees Operating Michigan State University Methods to extend vision to infrared wavelengths
US20040137059A1 (en) * 2003-01-09 2004-07-15 Thierry Nivaggioli Biodegradable ocular implant
US20050048099A1 (en) 2003-01-09 2005-03-03 Allergan, Inc. Ocular implant made by a double extrusion process
WO2004073551A2 (en) * 2003-02-18 2004-09-02 Massachusetts Eye And Ear Infirmary Transscleral drug delivery device and related methods
US9216106B2 (en) 2003-04-09 2015-12-22 Directcontact Llc Device and method for the delivery of drugs for the treatment of posterior segment disease
ATE476960T1 (de) * 2003-05-02 2010-08-15 Surmodics Inc System zur kontrollierten freisetzung eines bioaktiven wirkstoffs im hinteren bereich des auges
US8246974B2 (en) 2003-05-02 2012-08-21 Surmodics, Inc. Medical devices and methods for producing the same
US20040225250A1 (en) 2003-05-05 2004-11-11 Michael Yablonski Internal shunt and method for treating glaucoma
US7589107B2 (en) 2003-05-19 2009-09-15 Othera Holding, Inc. Amelioration of vitrectomy-induced cataracts
US20050009910A1 (en) * 2003-07-10 2005-01-13 Allergan, Inc. Delivery of an active drug to the posterior part of the eye via subconjunctival or periocular delivery of a prodrug
KR20060082792A (ko) * 2003-07-10 2006-07-19 알콘, 인코퍼레이티드 안과용 약물 전달 장치
EP1649028B1 (en) * 2003-07-25 2012-08-22 Genvec, Inc. Adenoviral vector-based vaccines
US7585517B2 (en) 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
US20070224278A1 (en) * 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
WO2005048873A2 (en) * 2003-11-12 2005-06-02 Alcon, Inc. Kit for administration of a drug
US20060141049A1 (en) * 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
AU2004292957C1 (en) * 2003-11-13 2011-04-28 Eyepoint Pharmaceuticals Us, Inc. Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin
US7291125B2 (en) * 2003-11-14 2007-11-06 Transcend Medical, Inc. Ocular pressure regulation
DE602004025726D1 (de) * 2003-11-14 2010-04-08 Genvec Inc Pharmazeutische verbindung zur behandlung von lokal fortgeschrittenem primär inoperablen pankreaskarzinom (lapc).
CN100558360C (zh) 2003-11-20 2009-11-11 奥特拉控股公司 羟胺组合物在制备缓解黄斑变性和其他眼科疾病的药物中的用途
US20080220049A1 (en) * 2003-12-05 2008-09-11 Adnexus, A Bristol-Myers Squibb R&D Company Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins
AU2004296376B2 (en) 2003-12-05 2010-03-04 Bristol-Myers Squibb Company Inhibitors of type 2 vascular endothelial growth factor receptors
US7211272B2 (en) * 2003-12-22 2007-05-01 Bausch & Lomb Incorporated Drug delivery device
CA2553381C (en) 2004-01-20 2011-03-22 Allergan, Inc. Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
US20050250788A1 (en) * 2004-01-30 2005-11-10 Hosheng Tu Aqueous outflow enhancement with vasodilated aqueous cavity
US20050220843A1 (en) 2004-04-06 2005-10-06 Dewitt David M Coating compositions for bioactive agents
EP1737885A2 (en) 2004-04-12 2007-01-03 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Method of using adenoviral vectors to induce an immune response
US7691381B2 (en) * 2004-04-15 2010-04-06 Allergan, Inc. Stabilized biodegradable neurotoxin implants
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
US9549895B2 (en) * 2004-04-23 2017-01-24 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
JP2007535386A (ja) * 2004-04-29 2007-12-06 アイサイエンス・インターベンショナル・コーポレーション 房水排出の外科的強化のための装置
US20080058704A1 (en) * 2004-04-29 2008-03-06 Michael Hee Apparatus and Method for Ocular Treatment
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8529927B2 (en) * 2004-04-30 2013-09-10 Allergan, Inc. Alpha-2 agonist polymeric drug delivery systems
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20060182781A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Methods for treating ocular conditions with cyclic lipid contraining microparticles
US7771742B2 (en) 2004-04-30 2010-08-10 Allergan, Inc. Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
US20050244471A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Estradiol derivative and estratopone containing sustained release intraocular implants and related methods
US20050244500A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Intravitreal implants in conjuction with photodynamic therapy to improve vision
AU2011213904B2 (en) * 2004-04-30 2014-06-05 Allergan, Inc. Sustained release intraocular implants comprising a beta adrenergic receptor antagonist and methods for treating ocular neuropathies
US8673341B2 (en) 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US20050244465A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Drug delivery systems and methods for treatment of an eye
US20070059336A1 (en) * 2004-04-30 2007-03-15 Allergan, Inc. Anti-angiogenic sustained release intraocular implants and related methods
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US7589057B2 (en) 2004-04-30 2009-09-15 Allergan, Inc. Oil-in-water method for making alpha-2 agonist polymeric drug delivery systems
BRPI0510485A (pt) 2004-04-30 2007-11-13 Allergan Inc implantes inibidores de tirosina cinase intravìtreos biodegradáveis
US20050244458A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular neuropathies
US8591885B2 (en) * 2004-04-30 2013-11-26 Allergan, Inc. Carbonic anhydrase inhibitor sustained release intraocular drug delivery systems
US20050244462A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Devices and methods for treating a mammalian eye
US20050244478A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Anti-excititoxic sustained release intraocular implants and related methods
US20050244461A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Controlled release drug delivery systems and methods for treatment of an eye
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
WO2005110374A1 (en) 2004-04-30 2005-11-24 Allergan, Inc. Intraocular drug delivery systems containing a therapeutic component, a cyclodextrin, and a polymeric component
US20070212395A1 (en) * 2006-03-08 2007-09-13 Allergan, Inc. Ocular therapy using sirtuin-activating agents
US8425929B2 (en) * 2004-04-30 2013-04-23 Allergan, Inc. Sustained release intraocular implants and methods for preventing retinal dysfunction
US20060182783A1 (en) * 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US8119154B2 (en) * 2004-04-30 2012-02-21 Allergan, Inc. Sustained release intraocular implants and related methods
US20050244466A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Photodynamic therapy in conjunction with intraocular implants
US8147865B2 (en) 2004-04-30 2012-04-03 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US8685435B2 (en) 2004-04-30 2014-04-01 Allergan, Inc. Extended release biodegradable ocular implants
US20050244463A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Sustained release intraocular implants and methods for treating ocular vasculopathies
CA2572223C (en) 2004-06-25 2014-08-12 The Johns Hopkins University Angiogenesis inhibitors
US20060110428A1 (en) * 2004-07-02 2006-05-25 Eugene Dejuan Methods and devices for the treatment of ocular conditions
US7922702B2 (en) 2004-07-02 2011-04-12 Qlt Inc. Treatment medium delivery device and methods for delivery of such treatment mediums to the eye using such a delivery device
EP2216026B1 (en) * 2004-07-12 2016-04-20 Allergan, Inc. Ophthalmic compositions and uses for treating ophthalmic conditions
JP4772045B2 (ja) 2004-07-16 2011-09-14 アメリカ合衆国 Ｃｍｖ／ｒ核酸コンストラクトを含むａｉｄｓに対するワクチン
US7117870B2 (en) * 2004-07-26 2006-10-10 Clarity Corporation Lacrimal insert having reservoir with controlled release of medication and method of manufacturing the same
ES2432556T3 (es) 2004-08-04 2013-12-04 Evonik Corporation Métodos para fabricar dispositivos de suministro y sus dispositivos
US7722669B2 (en) 2004-08-13 2010-05-25 Richard Foulkes Method and insert for modifying eye color
US8246569B1 (en) 2004-08-17 2012-08-21 California Institute Of Technology Implantable intraocular pressure drain
US20060047250A1 (en) * 2004-08-30 2006-03-02 Hickingbotham Dyson W Fluid delivery device
JP2008511336A (ja) * 2004-09-01 2008-04-17 アメリカ合衆国 免疫原性が増加したアデノウイルスベクターをインビボで用いる方法
CN100428958C (zh) * 2004-09-06 2008-10-29 段亚东 一种治疗眼病的植入剂
MX366832B (es) 2004-10-01 2019-07-24 Ramscor Inc Composiciones de farmaco de liberacion sostenida convenientemente implantables.
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US7226435B2 (en) * 2004-10-14 2007-06-05 Alcon, Inc. Drug delivery device
WO2006043965A1 (en) * 2004-10-14 2006-04-27 Allergan, Inc. Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
US20060089590A1 (en) * 2004-10-27 2006-04-27 John Higuchi Methods and devices for sustained in-vivo release of an active agent
US20060107555A1 (en) * 2004-11-09 2006-05-25 Curtis Marc D Universal snow plow adapter
BRPI0608152A2 (pt) 2005-02-09 2009-11-10 Macusight Inc formulações para tratamento ocular
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
US20060257450A1 (en) * 2005-03-21 2006-11-16 Sreenivasu Mudumba Drug delivery systems for treatment of diseases or conditions
US7785291B2 (en) * 2005-03-01 2010-08-31 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
US7699863B2 (en) * 2005-03-01 2010-04-20 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
US20060204548A1 (en) 2005-03-01 2006-09-14 Allergan, Inc. Microimplants for ocular administration
US20060233858A1 (en) * 2005-03-08 2006-10-19 Allergan, Inc. Systems and methods providing targeted intraocular drug delivery
JP4584331B2 (ja) * 2005-03-11 2010-11-17 インデバス ファーマシューティカルズ、インク． オクトレオチドの放出制御製剤
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
US7931909B2 (en) 2005-05-10 2011-04-26 Allergan, Inc. Ocular therapy using alpha-2 adrenergic receptor compounds having enhanced anterior clearance rates
US20060258994A1 (en) * 2005-05-12 2006-11-16 Avery Robert L Implantable delivery device for administering pharmacological agents to an internal portion of a body
US20080312283A1 (en) * 2005-05-26 2008-12-18 Othera Pharmaceuticals, Inc. Use of Hydroxylamine Derivates for Inhibiting Vitrectomy-Induced Cataracts
EP1919365A2 (en) * 2005-07-13 2008-05-14 Anthrogenesis Corporation Ocular plug formed from placenta derived collagen biofabric
JP2009501725A (ja) * 2005-07-15 2009-01-22 チャクシュ・リサーチ・インコーポレーテッド 糖尿病の眼科合併症の予防及び治療
KR20080033463A (ko) 2005-07-27 2008-04-16 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 단백질 미스폴딩을 보정하는 작은 화합물 및 그의 용도
US7592330B2 (en) * 2005-08-08 2009-09-22 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving the viability of photoreceptor cells
US20070060887A1 (en) * 2005-08-22 2007-03-15 Marsh David A Ophthalmic injector
CA2620495A1 (en) * 2005-08-31 2007-03-08 Genvec, Inc. Adenoviral vector-based malaria vaccines
CA2602440A1 (en) * 2005-09-16 2007-04-05 Allergan, Inc. Compositions and methods for the intraocular transport of therapeutic agents
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
CN101394834A (zh) 2005-10-18 2009-03-25 阿勒根公司 用糖皮质激素衍生物选择性渗透后段组织来治疗眼睛
US9067047B2 (en) * 2005-11-09 2015-06-30 The Invention Science Fund I, Llc Injectable controlled release fluid delivery system
WO2007059461A2 (en) * 2005-11-10 2007-05-24 Genvec, Inc. Adenoviral vector-based foot-and-mouth disease vaccine
US20080293691A1 (en) 2005-11-29 2008-11-27 Smithkline Beecham Corporation Treatment Method
PL2526910T3 (pl) 2006-01-17 2016-01-29 Novartis Ag Urządzenie do leczenia jaskry
WO2007084582A2 (en) * 2006-01-17 2007-07-26 Forsight Labs, Llc Drug delivery treatment device
US7756524B1 (en) 2006-01-31 2010-07-13 Nextel Communications Inc. System and method for partially count-based allocation of vocoder resources
US20070178138A1 (en) * 2006-02-01 2007-08-02 Allergan, Inc. Biodegradable non-opthalmic implants and related methods
EP2407171A3 (en) 2006-02-02 2012-04-11 Allergan, Inc. Compositions and methods for the treatment of ophthalmic disease
WO2007092620A2 (en) 2006-02-09 2007-08-16 Macusight, Inc. Stable formulations, and methods of their preparation and use
US20070203190A1 (en) * 2006-02-22 2007-08-30 Ghanshyam Patil Hydroxylamines and derivatives for the inhibition of complement activation
US20070202186A1 (en) * 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
US20080140057A1 (en) * 2006-03-09 2008-06-12 Searete Llc, A Limited Liability Corporation Of State Of The Delaware Injectable controlled release fluid delivery system
ES2493921T3 (es) * 2006-03-14 2014-09-12 University Of Southern California Dispositivo MEMS para la administración de agentes terapéuticos
CA2645488C (en) 2006-03-23 2014-09-02 Macusight, Inc. Formulations comprising rapamycin and methods using same for vascular permeability-related diseases or conditions
JP2009532132A (ja) 2006-03-31 2009-09-10 キューエルティー プラグ デリバリー，インク． 薬物治療用鼻涙排液系インプラント
US8676293B2 (en) * 2006-04-13 2014-03-18 Aecc Enterprises Ltd. Devices, systems and methods for measuring and evaluating the motion and function of joint structures and associated muscles, determining suitability for orthopedic intervention, and evaluating efficacy of orthopedic intervention
US20070293807A1 (en) * 2006-05-01 2007-12-20 Lynch Mary G Dual drainage pathway shunt device and method for treating glaucoma
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
US20070270750A1 (en) * 2006-05-17 2007-11-22 Alcon, Inc. Drug delivery device
US20070270744A1 (en) * 2006-05-17 2007-11-22 Bruno Dacquay Limited Reuse Assembly For Ophthalmic Injection Device
US7674243B2 (en) * 2006-05-17 2010-03-09 Alcon Inc. Ophthalmic injection device using piezoelectric array
US7862540B2 (en) * 2006-05-17 2011-01-04 Alcon Research, Ltd. Ophthalmic injection device using shape memory alloy
US7887521B2 (en) * 2006-05-17 2011-02-15 Alcon Research, Ltd. Ophthalmic injection system
US7811252B2 (en) * 2006-05-17 2010-10-12 Alcon Research, Ltd. Dosage control device
US20070270768A1 (en) * 2006-05-17 2007-11-22 Bruno Dacquay Mechanical Linkage Mechanism For Ophthalmic Injection Device
US20070268340A1 (en) * 2006-05-17 2007-11-22 Bruno Dacquay Ophthalmic Injection System and Method Using Piezoelectric Array
US8668676B2 (en) * 2006-06-19 2014-03-11 Allergan, Inc. Apparatus and methods for implanting particulate ocular implants
US8802128B2 (en) 2006-06-23 2014-08-12 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20070298073A1 (en) * 2006-06-23 2007-12-27 Allergan, Inc. Steroid-containing sustained release intraocular implants and related methods
US20120123316A1 (en) 2010-11-15 2012-05-17 Aquesys, Inc. Intraocular shunts for placement in the intra-tenon's space
US8308701B2 (en) 2010-11-15 2012-11-13 Aquesys, Inc. Methods for deploying intraocular shunts
CA2655969C (en) 2006-06-30 2014-11-25 Aquesys Inc. Methods, systems and apparatus for relieving pressure in an organ
US10085884B2 (en) 2006-06-30 2018-10-02 Aquesys, Inc. Intraocular devices
US8852256B2 (en) 2010-11-15 2014-10-07 Aquesys, Inc. Methods for intraocular shunt placement
US8663303B2 (en) 2010-11-15 2014-03-04 Aquesys, Inc. Methods for deploying an intraocular shunt from a deployment device and into an eye
US8721702B2 (en) 2010-11-15 2014-05-13 Aquesys, Inc. Intraocular shunt deployment devices
US9095411B2 (en) 2010-11-15 2015-08-04 Aquesys, Inc. Devices for deploying intraocular shunts
US8911496B2 (en) 2006-07-11 2014-12-16 Refocus Group, Inc. Scleral prosthesis for treating presbyopia and other eye disorders and related devices and methods
KR101351863B1 (ko) 2006-07-11 2014-01-15 리포쿠스 그룹 인코포레이티드 노안 및 다른 눈 질환을 치료하기 위한 공 인공 보철물 및 관련 장치 및 방법
US20080097335A1 (en) * 2006-08-04 2008-04-24 Allergan, Inc. Ocular implant delivery assemblies
US20100105707A1 (en) * 2006-08-23 2010-04-29 The United States Of America Method of treating or preventing oxidative stress-related disease
EP2059282A4 (en) * 2006-09-06 2014-04-09 Innfocus Inc APPARATUS, METHODS AND DEVICES FOR THE TREATMENT OF OCULAR DISORDERS
US20080125712A1 (en) * 2006-09-26 2008-05-29 Alcon Manufacturing, Ltd. Ophthalmic injection system
US20080097379A1 (en) * 2006-09-26 2008-04-24 Alcon Manufacturing, Ltd. Ophthalmic injection method
US20080097390A1 (en) * 2006-09-27 2008-04-24 Alcon Manufacturing, Ltd. Spring actuated delivery system
JP5694664B2 (ja) * 2006-09-29 2015-04-01 サーモディクス，インコーポレイティド 生分解性眼用インプラント及び眼の病気を治療する方法
US20080091178A1 (en) * 2006-10-11 2008-04-17 Sunalp Murad A Device and method for medical records storage in the eye
KR20090067218A (ko) * 2006-10-16 2009-06-24 알콘 리서치, 리미티드 일회용 단부를 구비하는 안과용 핸드 피스의 작동 방법
US20080281292A1 (en) * 2006-10-16 2008-11-13 Hickingbotham Dyson W Retractable Injection Port
US9022970B2 (en) * 2006-10-16 2015-05-05 Alcon Research, Ltd. Ophthalmic injection device including dosage control device
ES2355960T3 (es) * 2006-10-16 2011-04-01 Alcon Research, Ltd. Conjunto de reutilización limitada recargable univaersal para pieza de mano oftálmica.
US8586556B2 (en) 2006-11-03 2013-11-19 Allergan, Inc. Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules
US8039010B2 (en) 2006-11-03 2011-10-18 Allergan, Inc. Sustained release intraocular drug delivery systems comprising a water soluble therapeutic agent and a release modifier
EP2088976B1 (en) 2006-11-10 2019-07-03 Glaukos Corporation Uveoscleral shunt
WO2008063639A2 (en) 2006-11-21 2008-05-29 Massachusetts Eye And Ear Infirmary Compositions and methods for preserving cells of the eye
BRPI0719597A2 (pt) 2006-11-22 2013-12-17 Adnexus A Bristol Myers Squibb R & D Company Produtos terapêuticos objetivados baseados em proteínas manipuladas para receptores de quinases de tirosina, incluindo igf-ir
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
WO2008070479A2 (en) 2006-12-01 2008-06-12 Allergan, Inc. Method for determining optimum intraocular locations for drug delivery systems
WO2008073576A1 (en) * 2006-12-08 2008-06-19 Alcon, Inc. Drug delivery device
US8846073B2 (en) 2006-12-19 2014-09-30 Allergan, Inc. Low temperature processes for making cyclic lipid implants for intraocular use
US20090092574A1 (en) 2006-12-29 2009-04-09 Scott Richard W Ophthalmic And Otic Compositions Of Facially Amphiphilic Polymers And Oligomers And Uses Thereof
EP2114445A2 (en) * 2007-01-09 2009-11-11 Genvec, Inc. Adenoviral vector-based malaria vaccines
JP4957258B2 (ja) * 2007-01-15 2012-06-20 富士通株式会社 歩数計数装置および歩数計数方法
GB0713463D0 (en) 2007-07-11 2007-08-22 Btg Int Ltd Modulators of hypoxia inducible factor-1 and related uses
US7911053B2 (en) * 2007-04-19 2011-03-22 Marvell World Trade Ltd. Semiconductor packaging with internal wiring bus
US20080265343A1 (en) * 2007-04-26 2008-10-30 International Business Machines Corporation Field effect transistor with inverted t shaped gate electrode and methods for fabrication thereof
US8231892B2 (en) 2007-05-24 2012-07-31 Allergan, Inc. Biodegradable drug delivery system
US8492334B2 (en) * 2007-06-21 2013-07-23 Yale University Sustained intraocular delivery of drugs from biodegradable polymeric microparticles
US20090018548A1 (en) * 2007-07-13 2009-01-15 Charles Steven T Pneumatically-Powered Intraocular Lens Injection Device with Removable Cartridge
US20090018512A1 (en) * 2007-07-13 2009-01-15 Charles Steven T Pneumatically-Powered Ophthalmic Injector
US8672870B2 (en) 2007-07-17 2014-03-18 Transcend Medical, Inc. Ocular implant with hydrogel expansion capabilities
US7740619B2 (en) * 2007-08-01 2010-06-22 Alcon Research, Ltd. Spring driven ophthalmic injection device with safety actuator lockout feature
WO2009018440A1 (en) * 2007-08-02 2009-02-05 Refocus Group, Inc. Scleral prosthesis having crossbars for treating presbyopia and other eye disorders
US20090036842A1 (en) * 2007-08-03 2009-02-05 Raffi Pinedjian Consumable Activation Lever For Injection Device
US7629768B2 (en) * 2007-08-03 2009-12-08 Alcon Research, Ltd. Easy cleaning C-shaped charging base
RU2010112417A (ru) 2007-09-07 2011-10-10 Клт Плаг Диливери, Инк. (Us) Обнаружение лакримальных имплантатов
TWI498136B (zh) * 2007-10-09 2015-09-01 Alcon Res Ltd 用於遞送速率及溫度相依性物質至眼睛的注射器及其製備方法
TWI451862B (zh) * 2007-10-09 2014-09-11 Alcon Res Ltd 用於眼睛注射的熱係數驅動藥丸尺寸
US20090099481A1 (en) 2007-10-10 2009-04-16 Adam Deitz Devices, Systems and Methods for Measuring and Evaluating the Motion and Function of Joints and Associated Muscles
JP5330401B2 (ja) 2007-11-08 2013-10-30 アリメラ・サイエンシーズ，インコーポレーテッド 眼のための埋め込み装置、及びその装置を備えるキット
US8728528B2 (en) 2007-12-20 2014-05-20 Evonik Corporation Process for preparing microparticles having a low residual solvent volume
ES2425769T5 (es) 2007-12-20 2017-07-28 University Of Southern California Aparato para la administración de agentes terapéuticos
US20090162417A1 (en) * 2007-12-21 2009-06-25 Cook Incorporated Drug eluting ocular conformer
EP2240220B1 (en) * 2008-01-03 2016-04-13 University Of Southern California Implantable drug-delivery devices, and apparatus for refilling the devices
US8602959B1 (en) * 2010-05-21 2013-12-10 Robert Park Methods and devices for delivery of radiation to the posterior portion of the eye
WO2009102421A2 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind egfr
US20100152646A1 (en) * 2008-02-29 2010-06-17 Reshma Girijavallabhan Intravitreal injection device and method
US20090227938A1 (en) * 2008-03-05 2009-09-10 Insitu Therapeutics, Inc. Wound Closure Devices, Methods of Use, and Kits
EP2320989B1 (en) * 2008-05-08 2015-03-11 MiniPumps, LLC Implantable pumps and cannulas therefor
US9333297B2 (en) 2008-05-08 2016-05-10 Minipumps, Llc Drug-delivery pump with intelligent control
US8231608B2 (en) 2008-05-08 2012-07-31 Minipumps, Llc Drug-delivery pumps and methods of manufacture
EP2320972B1 (en) 2008-05-08 2020-07-01 MiniPumps, LLC Implantable drug-delivery devices
US9877973B2 (en) 2008-05-12 2018-01-30 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
US9095404B2 (en) 2008-05-12 2015-08-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
CN102026599A (zh) 2008-05-12 2011-04-20 犹他大学研究基金会 眼内药物递送装置及相关方法
US10064819B2 (en) 2008-05-12 2018-09-04 University Of Utah Research Foundation Intraocular drug delivery device and associated methods
JP2011520961A (ja) 2008-05-22 2011-07-21 ブリストル−マイヤーズ スクイブ カンパニー 多価フィブロネクチンをベースとする足場ドメインタンパク質
US8617139B2 (en) 2008-06-25 2013-12-31 Transcend Medical, Inc. Ocular implant with shape change capabilities
US8283350B2 (en) 2008-08-01 2012-10-09 Alpha Synergy Development, Inc. Compositions and methods for reducing capillary permeability
WO2010024930A2 (en) 2008-08-28 2010-03-04 President And Fellows Of Harvard College Cortistatin analogues and syntheses therof
US20100121441A1 (en) * 2008-11-10 2010-05-13 Nabil Jabbour Surgical implant and method
US9095506B2 (en) 2008-11-17 2015-08-04 Allergan, Inc. Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof
US8034813B2 (en) 2008-11-18 2011-10-11 Bausch & Lomb Incorporated Polymorphs of brimonidine pamoate
US20120232649A1 (en) 2008-11-20 2012-09-13 Insight Innovations, Llc Intraocular Lens Cell Migration Inhibition System
US9943402B2 (en) 2008-11-20 2018-04-17 Insight Innovations, Llc Micropatterned intraocular implant
US20110230963A1 (en) 2008-11-20 2011-09-22 Insight Innovations, Llc Biocompatible biodegradable intraocular implant system
US8551167B2 (en) 2008-11-20 2013-10-08 Insight Innovations, Llc Intraocular implant cell migration inhibition system
TWI496582B (zh) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 雙重專一性之ｅｇｆｒ／ｉｇｆｉｒ結合分子
US20100158980A1 (en) 2008-12-18 2010-06-24 Casey Kopczynski Drug delivery devices for delivery of therapeutic agents
US8545554B2 (en) * 2009-01-16 2013-10-01 Allergan, Inc. Intraocular injector
US8425473B2 (en) 2009-01-23 2013-04-23 Iscience Interventional Corporation Subretinal access device
US20100191177A1 (en) * 2009-01-23 2010-07-29 Iscience Interventional Corporation Device for aspirating fluids
US8377122B2 (en) 2009-01-28 2013-02-19 Transcend Medical, Inc. Ocular implant with stiffness qualities, methods of implantation and system
CA3045436A1 (en) 2009-01-29 2010-08-05 Forsight Vision4, Inc. Posterior segment drug delivery
US8623395B2 (en) 2010-01-29 2014-01-07 Forsight Vision4, Inc. Implantable therapeutic device
US9636255B2 (en) 2009-02-13 2017-05-02 Dose Medical Corporation Uveoscleral drug delivery implant and methods for implanting the same
WO2010096561A1 (en) 2009-02-18 2010-08-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Synthetic hiv/siv gag proteins and uses thereof
JP5342301B2 (ja) * 2009-03-30 2013-11-13 三菱重工業株式会社 太陽光集光受熱器
US8632511B2 (en) 2009-05-06 2014-01-21 Alcon Research, Ltd. Multiple thermal sensors in a multiple processor environment for temperature control in a drug delivery device
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
EP4108216A1 (en) 2009-06-03 2022-12-28 Forsight Vision5, Inc. Anterior segment drug delivery
IN2012DN00352A (ko) 2009-06-16 2015-08-21 Bikam Pharmaceuticals Inc
WO2010148352A1 (en) 2009-06-19 2010-12-23 Altos Vision Limited Time-release and micro-dose formulations for topical application of estrogen and estrogen analogs or other estrogen receptor modulators in the treatment of dry eye syndrome, and methods of preparation and application
EP2467797B1 (en) 2009-08-18 2017-07-19 MiniPumps, LLC Electrolytic drug-delivery pump with adaptive control
US9605844B2 (en) * 2009-09-01 2017-03-28 Cree, Inc. Lighting device with heat dissipation elements
US9138163B2 (en) 2009-09-25 2015-09-22 Ortho Kinematics, Inc. Systems and devices for an integrated imaging system with real-time feedback loop and methods therefor
WO2011039648A1 (en) 2009-09-30 2011-04-07 Glaxo Wellcome Manufacturing Pte Ltd. Methods of administration and treatment
US20120219583A1 (en) 2009-10-16 2012-08-30 Los Alamos National Security, Llc Nucleic acid sequences encoding expandable hiv mosaic proteins
JP5886204B2 (ja) * 2009-10-30 2016-03-16 アトーン ファルマ、インコーポレイテッドＡｔｏｎ Ｐｈａｒｍａ，Ｉｎｃ． 眼内薬剤送達装置
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
JP5982287B2 (ja) 2009-11-09 2016-08-31 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 発毛を刺激する組成物および方法
EP2498778A1 (en) 2009-11-13 2012-09-19 The United States Of America, As Represented By The Secretary, Department of Health and Human Services Diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer
US8177747B2 (en) 2009-12-22 2012-05-15 Alcon Research, Ltd. Method and apparatus for drug delivery
US8529492B2 (en) 2009-12-23 2013-09-10 Trascend Medical, Inc. Drug delivery devices and methods
EP2515864A4 (en) * 2009-12-23 2013-09-11 Psivida Inc DELAYED RELEASE DELIVERY DEVICES
WO2013022801A1 (en) 2011-08-05 2013-02-14 Forsight Vision4, Inc. Small molecule delivery with implantable therapeutic device
WO2011106697A1 (en) 2010-02-25 2011-09-01 Schepens Eye Research Institute Therapeutic compositions for the treatment of dry eye disease
EP2547362B1 (en) 2010-03-17 2021-08-25 Cornell University Disrupted adenovirus-based vaccine against drugs of abuse
WO2011116336A1 (en) 2010-03-19 2011-09-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxyl (hno) releasing compounds and uses thereof in treating diseases
WO2011133964A2 (en) 2010-04-23 2011-10-27 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving photoreceptor and retinal pigment epithelial cells
EP2383286A1 (en) 2010-04-30 2011-11-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for treatment of retinal degenerative diseases
SG185383A1 (en) 2010-04-30 2012-12-28 Alexion Pharma Inc Anti-c5a antibodies and methods for using the antibodies
JP2013526572A (ja) * 2010-05-17 2013-06-24 アエリエ・ファーマシューティカルズ・インコーポレーテッド 眼治療薬の送達のための薬物送達装置
US9562089B2 (en) 2010-05-26 2017-02-07 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
US8939948B2 (en) 2010-06-01 2015-01-27 Forsight Vision5, Inc. Ocular insert apparatus and methods
US9033911B2 (en) 2010-08-05 2015-05-19 Forsight Vision4, Inc. Injector apparatus and method for drug delivery
WO2012019139A1 (en) 2010-08-05 2012-02-09 Forsight Vision4, Inc. Combined drug delivery methods and apparatus
JP5907966B2 (ja) * 2010-08-05 2016-04-26 フォーサイト・ビジョン フォー・インコーポレーテッド 埋め込み型治療デバイス
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
EP3520749A1 (en) 2010-10-15 2019-08-07 Clearside Biomedical, Inc. Device for ocular access
WO2012061045A2 (en) 2010-11-01 2012-05-10 Massachusetts Eye And Ear Infirmary Methods and compositions for preserving retinal ganglion cells
US20160256319A1 (en) 2010-11-15 2016-09-08 Aquesys, Inc. Intraocular shunt placement in the suprachoroidal space
EP2640360A2 (en) 2010-11-19 2013-09-25 Forsight Vision4, Inc. Therapeutic agent formulations for implanted devices
US9668915B2 (en) 2010-11-24 2017-06-06 Dose Medical Corporation Drug eluting ocular implant
EP2651295A4 (en) 2010-12-13 2015-11-18 Ortho Kinematics Inc METHODS, SYSTEMS AND DEVICES FOR CLINICAL DATA REPORTING AND SURGICAL NAVIGATION
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
EP2654786B1 (en) 2010-12-20 2019-02-20 GenVec, Inc. Adenoviral vector-based dengue fever vaccine
WO2012114138A1 (fr) * 2011-02-21 2012-08-30 Cerebel-Invest Sa Implants biodégradables pour la libération contrôlée sous-conjonctivale d'une molécule active
US10286146B2 (en) 2011-03-14 2019-05-14 Minipumps, Llc Implantable drug pumps and refill devices therefor
US9919099B2 (en) 2011-03-14 2018-03-20 Minipumps, Llc Implantable drug pumps and refill devices therefor
US9603997B2 (en) 2011-03-14 2017-03-28 Minipumps, Llc Implantable drug pumps and refill devices therefor
US8992503B2 (en) 2011-03-27 2015-03-31 Microsert Ltd. Miniature implanted drug delivery devices and inserter systems for introducing such devices
US9012647B2 (en) 2011-04-07 2015-04-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide modified non-steroidal anti-inflammatory compounds and uses thereof in the treatment and prevention of diseases or disorders
US8889672B2 (en) 2011-04-29 2014-11-18 The Regents Of The University Of Michigan Compounds, formulations, and methods of protein kinase C inhibition
WO2012162428A1 (en) 2011-05-23 2012-11-29 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Prime-boost vaccination for viral infection
WO2012167223A1 (en) 2011-06-02 2012-12-06 Massachusetts Institute Of Technology Modified alginates for cell encapsulation and cell therapy
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
JP6068457B2 (ja) 2011-06-14 2017-01-25 ビカム ファーマスーティカルス，インコーポレイテッド 化合物及び組成物
WO2013003467A2 (en) 2011-06-27 2013-01-03 Massachusetts Eye And Ear Infirmary Methods for treating ocular inflammatory disorders
WO2013003620A2 (en) 2011-06-28 2013-01-03 Forsight Vision4, Inc. Diagnostic methods and apparatus
US9724357B2 (en) 2011-08-15 2017-08-08 Massachusetts Eye & Ear Infirmary Methods for preserving photoreceptor cell viability following retinal detachment
WO2013040079A1 (en) 2011-09-13 2013-03-21 Dose Medical Corporation Intraocular physiological sensor
EP3903733A1 (en) 2011-09-16 2021-11-03 ForSight Vision4, Inc. Fluid exchange apparatus
RU2014118642A (ru) 2011-10-12 2015-11-20 Асцендис Фарма Офтальмолоджи Дивижн А/С Предотвращение и лечение глазных нарушений
EP2768307B1 (en) 2011-10-19 2020-03-18 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
EP2773341A2 (en) 2011-10-21 2014-09-10 Massachusetts Eye & Ear Infirmary Compositions comprising necrosis inhibitors, such as necrostatins, alone or in combination, for promoting axon regeneration and nerve function, thereby treating cns disorders
US9353063B2 (en) 2011-11-30 2016-05-31 Bikam Pharmaceuticals, Inc. Opsin-binding ligands, compositions and methods of use
US10040749B2 (en) 2011-12-01 2018-08-07 Bikam Pharmaceuticals Inc. Opsin-binding ligands, compositions and methods of use
US9808373B2 (en) 2013-06-28 2017-11-07 Aquesys, Inc. Intraocular shunt implantation
US10080682B2 (en) 2011-12-08 2018-09-25 Aquesys, Inc. Intrascleral shunt placement
US8765210B2 (en) 2011-12-08 2014-07-01 Aquesys, Inc. Systems and methods for making gelatin shunts
US9610195B2 (en) 2013-02-27 2017-04-04 Aquesys, Inc. Intraocular shunt implantation methods and devices
US8852136B2 (en) 2011-12-08 2014-10-07 Aquesys, Inc. Methods for placing a shunt into the intra-scleral space
US9241829B2 (en) 2011-12-20 2016-01-26 Abbott Medical Optics Inc. Implantable intraocular drug delivery apparatus, system and method
WO2013116061A1 (en) 2012-02-03 2013-08-08 Forsight Vision4, Inc. Insertion and removal methods and apparatus for therapeutic devices
US20150038557A1 (en) 2012-02-24 2015-02-05 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treatment of retinal degenerative diseases
US10093947B2 (en) 2012-02-28 2018-10-09 Cornell University AAV-directed persistent expression of an anti-nicotine antibody gene for smoking cessation
US10004811B2 (en) 2012-04-13 2018-06-26 Cornell University Development of a highly efficient second generation nicotine-conjugate vaccine to treat nicotine addiction
US10085633B2 (en) 2012-04-19 2018-10-02 Novartis Ag Direct visualization system for glaucoma treatment
US9241832B2 (en) 2012-04-24 2016-01-26 Transcend Medical, Inc. Delivery system for ocular implant
WO2013180967A1 (en) 2012-05-29 2013-12-05 Genvec, Inc. Herpes simplex virus vaccine
EP2855030B1 (en) 2012-06-01 2019-08-21 SurModics, Inc. Apparatus and method for coating balloon catheters
US9827401B2 (en) 2012-06-01 2017-11-28 Surmodics, Inc. Apparatus and methods for coating medical devices
WO2013183058A2 (en) 2012-06-07 2013-12-12 Tulip Medical Ltd. Expanded device
WO2014043698A2 (en) 2012-09-17 2014-03-20 Transcend Medical, Inc. Expanding ocular implant devices and methods
ES2709351T3 (es) 2012-09-27 2019-04-16 Allergan Inc Sistemas de administración de fármacos biodegradables para la liberación sostenida de proteínas
PT2911623T (pt) 2012-10-26 2019-11-21 Forsight Vision5 Inc Sistema oftálmico para libertação prolongada de fármaco no olho
BR112015010566A2 (pt) 2012-11-08 2017-07-11 Clearside Biomedical Inc métodos e dispositivos para o tratamento de doenças oculares em indivíduos humanos
US9763829B2 (en) 2012-11-14 2017-09-19 Novartis Ag Flow promoting ocular implant
CA2891673A1 (en) 2012-11-15 2014-05-22 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
WO2014093270A1 (en) 2012-12-10 2014-06-19 Virginia Commonwealth University Tropism modified cancer terminator virus (ad.5/3 ctv;ad.5/3-ctv-m7)
WO2014124458A1 (en) 2013-02-11 2014-08-14 The Regents Of The University Of California Compositions and methods for treating neurodegenerative diseases
RU2641021C2 (ru) 2013-02-15 2018-01-17 Аллерган, Инк. Имплантат для пролонгированной доставки лекарственного средства
CA2901226C (en) 2013-02-18 2020-11-17 Vegenics Pty Limited Vascular endothelial growth factor binding proteins
US10159600B2 (en) 2013-02-19 2018-12-25 Aquesys, Inc. Adjustable intraocular flow regulation
US9125723B2 (en) 2013-02-19 2015-09-08 Aquesys, Inc. Adjustable glaucoma implant
EP2970145B1 (en) 2013-03-11 2020-05-06 The Broad Institute, Inc. Compounds and compositions for the treatment of cancer
CA2940513C (en) 2013-03-11 2023-08-15 University Of Florida Research Foundation, Inc. Delivery of card protein as therapy for ocular inflammation
US9730638B2 (en) 2013-03-13 2017-08-15 Glaukos Corporation Intraocular physiological sensor
EP2968113B8 (en) 2013-03-14 2020-10-28 Forsight Vision4, Inc. Systems for sustained intraocular delivery of low solubility compounds from a port delivery system implant
US10517759B2 (en) 2013-03-15 2019-12-31 Glaukos Corporation Glaucoma stent and methods thereof for glaucoma treatment
US9592151B2 (en) 2013-03-15 2017-03-14 Glaukos Corporation Systems and methods for delivering an ocular implant to the suprachoroidal space within an eye
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
CA2907681C (en) 2013-03-28 2022-11-22 Forsight Vision4, Inc. Ophthalmic implant for delivering therapeutic substances
US9987163B2 (en) 2013-04-16 2018-06-05 Novartis Ag Device for dispensing intraocular substances
US10098836B2 (en) 2013-05-02 2018-10-16 Retina Foundation Of The Southwest Method for forming a molded two-layer ocular implant
WO2014179698A2 (en) 2013-05-03 2014-11-06 Clearside Biomedical, Inc. Apparatus and methods for ocular injection
US10274503B2 (en) 2013-05-08 2019-04-30 Vegenics Pty Limited Methods of using VEGF-C biomarkers for age-related macular degeneration (AMD) diagnosis
US20160355573A1 (en) 2013-09-05 2016-12-08 Cornell University Gene therapy for alzheimer's and other neurodegenerative diseases and conditions
KR102307281B1 (ko) 2013-10-31 2021-09-29 알레간 인코포레이티드 프로스타마이드-함유 안구내 삽입물 및 그것의 사용 방법
US10087224B2 (en) 2013-11-01 2018-10-02 Cornell University Gene therapy for Alzheimer's and other neurodegenerative diseases and conditions
LT3066201T (lt) 2013-11-07 2018-08-10 Editas Medicine, Inc. Su crispr susiję būdai ir kompozicijos su valdančiomis grnr
ES2740352T3 (es) 2013-11-14 2020-02-05 Eyed Pharma Dispositivo ocular
CN108403215B (zh) 2013-11-14 2021-03-23 阿奎西斯公司 眼内分流器插入器
WO2015083171A1 (en) 2013-12-05 2015-06-11 Tulip Medical Ltd. Retentive devices and systems for in-situ release of pharmaceutical active agents
US10010447B2 (en) 2013-12-18 2018-07-03 Novartis Ag Systems and methods for subretinal delivery of therapeutic agents
JP6494631B2 (ja) 2013-12-24 2019-04-03 プレジデント アンド フェローズ オブ ハーバード カレッジ コルチスタチン類縁体並びにその合成及び使用
US10143703B2 (en) 2014-01-02 2018-12-04 Massachusetts Eye And Ear Infirmary Treating ocular neovascularization
WO2015112739A1 (en) 2014-01-22 2015-07-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds and method for treating parp1-deficient cancers
US10167286B2 (en) 2014-02-11 2019-01-01 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
EP3957735A1 (en) 2014-03-05 2022-02-23 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
US11339437B2 (en) 2014-03-10 2022-05-24 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
EP3553176A1 (en) 2014-03-10 2019-10-16 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10)
US11141493B2 (en) 2014-03-10 2021-10-12 Editas Medicine, Inc. Compositions and methods for treating CEP290-associated disease
JP6655610B2 (ja) 2014-05-29 2020-02-26 グローコス コーポレーション 制御された薬物送達機能を備えるインプラント及びそれを使用する方法
RU2695563C2 (ru) 2014-07-15 2019-07-24 Форсайт Вижн4, Инк. Способ и устройство для доставки глазного имплантата
CN106795225B (zh) 2014-08-01 2021-03-19 麻省理工学院 用于抗纤维化材料的修饰的藻酸盐以及应用
US9474756B2 (en) 2014-08-08 2016-10-25 Forsight Vision4, Inc. Stable and soluble formulations of receptor tyrosine kinase inhibitors, and methods of preparation thereof
CN114587774A (zh) 2014-11-10 2022-06-07 弗赛特影像4股份有限公司 治疗眼睛的系统
FR3028410A1 (fr) 2014-11-18 2016-05-20 Pierre Coulon Implant capsulaire multifonctionnel
JP6878301B2 (ja) 2015-04-09 2021-05-26 コーネル ユニヴァーシティー アレルゲンに対する反応を予防するための遺伝子治療
US20160296532A1 (en) 2015-04-13 2016-10-13 Forsight Vision5, Inc. Ocular Insert Composition of a Semi-Crystalline or Crystalline Pharmaceutically Active Agent
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
WO2016183297A1 (en) 2015-05-12 2016-11-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aav isolate and fusion protein comprising nerve growth factor signal peptide and parathyroid hormone
US10214731B2 (en) 2015-05-28 2019-02-26 Cornell University Adeno-associated virus mediated delivery of C1E1 as a therapy for angioedema
AU2016270974B2 (en) 2015-06-03 2018-08-23 Aquesys, Inc. Ab externo intraocular shunt placement
US20160354161A1 (en) 2015-06-05 2016-12-08 Ortho Kinematics, Inc. Methods for data processing for intra-operative navigation systems
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
WO2017040545A1 (en) 2015-09-02 2017-03-09 Trevena, Inc. 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
WO2017040853A1 (en) 2015-09-02 2017-03-09 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US10182939B2 (en) 2015-09-16 2019-01-22 Novartis Ag Hydraulic injector and methods for intra-ocular lens insertion
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
CN117503905A (zh) 2015-10-07 2024-02-06 阿佩利斯制药有限公司 给药方案
WO2017075475A1 (en) 2015-10-30 2017-05-04 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus
MX2018005420A (es) 2015-11-01 2018-06-06 Massachusetts Inst Technology Alginatos modificados para materiales anti-fibroticos y aplicaciones.
US11180538B2 (en) 2015-11-13 2021-11-23 University Of Utah Research Foundation Combinatorial gene construct and non-viral delivery for anti-obesity
KR20180084104A (ko) 2015-11-20 2018-07-24 포사이트 비젼4, 인크. 연장 방출 약물 전달 장치를 위한 다공성 구조물
US10390901B2 (en) 2016-02-10 2019-08-27 Clearside Biomedical, Inc. Ocular injection kit, packaging, and methods of use
AU2017221441A1 (en) 2016-02-17 2018-10-04 Children's Medical Center Corporation FFA1 (GPR40) as a therapeutic target for neural angiogenesis diseases or disorders
WO2017173327A1 (en) 2016-03-31 2017-10-05 The Schepens Eye Research Institute, Inc. Endomucin inhibitor as an anti-angiogenic agent
AR108177A1 (es) 2016-04-05 2018-07-25 Forsight Vision4 Inc Dispositivos de suministro de fármacos oculares implantables
JP7003110B2 (ja) 2016-04-20 2022-01-20 ドーズ メディカル コーポレーション 生体吸収性眼球薬物送達デバイス
WO2017192565A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
KR20190019966A (ko) 2016-06-02 2019-02-27 아큐시스, 인코포레이티드 안구내 약물 전달
CN109563199A (zh) 2016-06-13 2019-04-02 麻省理工学院 用于减少异物反应和纤维化的生物相容性两性离子聚合物涂层和水凝胶
CA3032822A1 (en) 2016-08-02 2018-02-08 Editas Medicine, Inc. Compositions and methods for treating cep290 associated disease
IL264764B2 (en) 2016-08-12 2024-02-01 Clearside Biomedical Inc Devices and methods for adjusting the insertion depth of a drug administration needle
CA3032153A1 (en) 2016-08-19 2018-02-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Selective estrogen-receptor modulators (serms) confer protection against photoreceptor degeneration
EP3532616A1 (en) 2016-10-28 2019-09-04 Editas Medicine, Inc. Crispr/cas-related methods and compositions for treating herpes simplex virus
WO2018093797A1 (en) 2016-11-15 2018-05-24 The Schepens Eye Research Institute, Inc. Compositions and methods for the treatment of aberrant angiogenesis
WO2018126225A1 (en) * 2016-12-29 2018-07-05 International Bioceutical Company, Llc Modular transdermal delivery system and associated methods of manufacture and use
WO2018152286A1 (en) 2017-02-17 2018-08-23 Trevena, Inc. 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
BR112019016827A2 (pt) 2017-02-17 2020-04-07 Trevena Inc compostos moduladores de receptor delta-opioide contendo aza-heterocíclico com 5 membros, métodos de uso e produção dos mesmos
CA3059304A1 (en) 2017-04-07 2018-10-11 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
ES2945740T3 (es) 2017-05-05 2023-07-06 Univ Pittsburgh Commonwealth Sys Higher Education Aplicaciones oculares de vesículas unidas a matriz (MBV)
CA3065474A1 (en) * 2017-05-30 2018-12-06 Eximore Ltd. Compositions and methods for treating dry eye syndrome delivering antibiotic macrolide
CA3067695A1 (en) 2017-06-21 2018-12-27 Mitokinin, Inc. Compositions and methods using the same for treatment of neurodegenerative and mitochondrial disease
CA3069804A1 (en) 2017-07-14 2019-01-17 Cytomx Therapeutics, Inc. Anti-cd166 antibodies and uses thereof
EP4218813A3 (en) 2017-07-27 2023-08-16 Alexion Pharmaceuticals, Inc. High concentration anti-c5 antibody formulations
CA3072673A1 (en) 2017-08-11 2019-02-14 Unity Biotechnology, Inc. Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
US20200209241A1 (en) 2017-09-15 2020-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
MX2020003339A (es) 2017-10-02 2020-11-06 Genedit Inc Arn guía de cpf1 modificado.
US11260048B2 (en) 2017-10-03 2022-03-01 The Schepens Eye Research Institute, Inc. Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same
JP7367988B2 (ja) 2017-10-18 2023-10-24 ワシントン・ユニバーシティ 神経変性の疾患または障害のための治療戦略としてのドミナントネガティブｓａｒｍ１分子
WO2019090309A1 (en) 2017-11-06 2019-05-09 Massachusetts Institute Of Technology Anti-inflammatory coatings to improve biocompatibility of neurological implants
US11246753B2 (en) 2017-11-08 2022-02-15 Aquesys, Inc. Manually adjustable intraocular flow regulation
WO2019099560A1 (en) 2017-11-14 2019-05-23 The Schepens Eye Research Institute, Inc. Runx1 inhibition for treatment of proliferative vitreoretinopathy and conditions associated with epithelial to mesenchymal transition
BR112020010053A2 (pt) 2017-11-21 2020-11-03 Forsight Vision4, Inc. aparelho para troca de fluido para sistema de liberação de porta expansível e métodos de uso do mesmo
WO2019133818A1 (en) 2017-12-29 2019-07-04 Cornell University Gene therapy for eosinohilic disorders
WO2019161378A1 (en) 2018-02-19 2019-08-22 University Of Miami Cyclophosphamide for treating ophthalmic inflammation
WO2019169291A1 (en) 2018-03-02 2019-09-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of il-34 to treat retinal inflammation and neurodegeneration
US10952898B2 (en) 2018-03-09 2021-03-23 Aquesys, Inc. Intraocular shunt inserter
US11135089B2 (en) 2018-03-09 2021-10-05 Aquesys, Inc. Intraocular shunt inserter
DE102018106217A1 (de) 2018-03-16 2019-09-19 Amw Gmbh Applikator
CA3095911A1 (en) 2018-04-03 2019-10-10 Cornell University Gene therapy for oxidative stress
US11821009B2 (en) 2018-05-15 2023-11-21 Cornell University Genetic modification of the AAV capsid resulting in altered tropism and enhanced vector delivery
MX2021001336A (es) 2018-07-31 2021-09-10 Univ Cornell Métodos de terapia génica para controlar la función de órganos.
WO2020112816A1 (en) 2018-11-29 2020-06-04 Surmodics, Inc. Apparatus and methods for coating medical devices
WO2020123691A2 (en) 2018-12-12 2020-06-18 Kite Pharma, Inc Chimeric antigen and t cell receptors and methods of use
US20220133768A1 (en) 2019-02-25 2022-05-05 Editas Medicine, Inc. Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp)
US11819590B2 (en) 2019-05-13 2023-11-21 Surmodics, Inc. Apparatus and methods for coating medical devices
JP2022538347A (ja) 2019-06-27 2022-09-01 レイヤーバイオ，インコーポレーテッド 眼用デバイス送達方法およびシステム
EP4007609A1 (en) 2019-08-01 2022-06-08 Cornell University Targeted gene therapy to treat neurological diseases
WO2021062012A1 (en) 2019-09-25 2021-04-01 Emory University Use of klk10 and engineered derivatizations thereof
EP4038222A4 (en) 2019-10-02 2023-10-18 Arizona Board of Regents on behalf of Arizona State University METHODS AND COMPOSITIONS FOR IDENTIFYING NEOANTIGENS FOR USE IN THE TREATMENT AND PREVENTION OF CANCER
JP2022552375A (ja) 2019-10-15 2022-12-15 コーネル・ユニバーシティー 遺伝子治療発現カセットからの発現レベルを調節するための方法
US11471426B2 (en) 2019-10-16 2022-10-18 American River Nutrition, Llc Compositions comprising quinone and/or quinol and methods of preparations and use thereof
US20230405148A1 (en) 2019-10-16 2023-12-21 Cornell University Gene therapy for alzheimer's disease
WO2021086973A2 (en) 2019-10-28 2021-05-06 University Of Iowa Research Foundation Formulation for delivery of lubricin gene
CN114829390A (zh) 2019-11-25 2022-07-29 康奈尔大学 Apoe基因疗法
AU2021208631A1 (en) 2020-01-17 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene therapy for treatment of CRX-autosomal dominant retinopathies
US11826421B2 (en) 2020-03-20 2023-11-28 Athanor Biosciences, Inc. Bacteriophage-based vaccines and engineered bacteriophage
WO2021207069A1 (en) 2020-04-05 2021-10-14 Athanor Biosciences, Inc. Bacteriophage-based antibodies and protein-based binders
EP4138921A1 (en) 2020-04-23 2023-03-01 University Of Iowa Research Foundation Gper proteolytic targeting chimeras
CA3176425A1 (en) 2020-04-24 2021-10-28 Millennium Pharmaceuticals, Inc. Anti-cd19 antibodies and uses thereof
WO2022006439A2 (en) 2020-07-02 2022-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compound embodiments for treating retinal degeneration and method embodiments of making and using the same
US20230374483A1 (en) 2020-07-08 2023-11-23 Regents Of The University Of Minnesota Modified hexosaminidase and uses thereof
WO2022036104A1 (en) 2020-08-12 2022-02-17 University Of Iowa Research Foundation Insulin sensitizers for the treatment of diabetes mellitus
WO2022040564A1 (en) 2020-08-21 2022-02-24 University Of Iowa Research Foundation Cationic nanoparticle adjuvants
WO2022047201A1 (en) 2020-08-27 2022-03-03 University Of Iowa Research Foundation Gene knock-out for treatment of glaucoma
US20240100183A1 (en) 2020-12-11 2024-03-28 University Of Iowa Research Foundation Compositions comprising molecules for cystic fibrosis treatment
CN117425673A (zh) 2021-04-09 2024-01-19 武田药品工业株式会社 靶向补体因子d的抗体和其用途
EP4323522A1 (en) 2021-04-16 2024-02-21 Editas Medicine, Inc. Crispr/rna-guided nuclease-related methods and compositions for treating rho-associated autosomal-dominant retinitis pigmentosa (adrp)
CA3214355A1 (en) 2021-04-26 2022-11-03 Antara Banerjee Anti-adgre2 antibodies and uses thereof
IL307939A (en) 2021-04-26 2023-12-01 Millennium Pharm Inc Anti-CLEC12A antibodies and uses thereof
WO2022246280A1 (en) 2021-05-21 2022-11-24 University Of Iowa Research Foundation Anti-oxidant containing particles and methods of use
WO2022271951A1 (en) 2021-06-23 2022-12-29 University Of Iowa Research Foundation Sustained release formulations comprising a selective androgen receptor modulator
KR20240026984A (ko) 2021-07-07 2024-02-29 제넨테크, 인크. 로드 삽입기 시스템 및 방법
WO2023068382A2 (en) 2021-10-20 2023-04-27 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof
WO2023105417A1 (en) 2021-12-06 2023-06-15 Breye Therapeutics Aps Danegaptide formulation for applicatoin in the eye
WO2023130022A2 (en) 2021-12-29 2023-07-06 University Of Iowa Research Foundation Cystatin rna compositions for tissue engineering
WO2023164727A1 (en) 2022-02-28 2023-08-31 University Of Iowa Research Foundation A-fabp antibodies for diagnosis and treatment of obesity-associated diseases
WO2023215293A1 (en) 2022-05-02 2023-11-09 Athanor Biosciences, Inc. Cancer eradicating – bio-nanoparticles (ce-bnp)
WO2023215560A1 (en) 2022-05-05 2023-11-09 Atoosa Corporation Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3923939A (en) * 1974-06-07 1975-12-02 Alza Corp Process for improving release kinetics of a monolithic drug delivery device
US4014335A (en) * 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4052505A (en) * 1975-05-30 1977-10-04 Alza Corporation Ocular therapeutic system manufactured from copolymer
US4057619A (en) * 1975-06-30 1977-11-08 Alza Corporation Ocular therapeutic system with selected membranes for administering ophthalmic drug
US4186184A (en) * 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4190642A (en) * 1978-04-17 1980-02-26 Alza Corporation Ocular therapeutic system for dispensing a medication formulation
US4210139A (en) * 1979-01-17 1980-07-01 Alza Corporation Osmotic device with compartment for governing concentration of agent dispensed from device
US4300557A (en) * 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
US4303637A (en) * 1980-04-04 1981-12-01 Alza Corporation Medication indicated for ocular hypertension
US4281654A (en) * 1980-04-07 1981-08-04 Alza Corporation Drug delivery system for controlled ocular therapy
US4304765A (en) * 1980-10-14 1981-12-08 Alza Corporation Ocular insert housing steroid in two different therapeutic forms
CA1206049A (en) * 1982-09-30 1986-06-17 Paul E. Michelson Osmotic device for physiological applications
US4478818A (en) * 1982-12-27 1984-10-23 Alza Corporation Ocular preparation housing steroid in two different therapeutic forms
US4853224A (en) * 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US4997652A (en) * 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US5098443A (en) * 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5028435A (en) * 1989-05-22 1991-07-02 Advanced Polymer Systems, Inc. System and method for transdermal drug delivery
US5164188A (en) * 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5178635A (en) * 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
US5330529A (en) * 1993-02-17 1994-07-19 Cepela Mark A Orbital implant device
US5443505A (en) * 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants

Also Published As

Publication number Publication date
ES2231781T3 (es) 2005-05-16
ATE274872T1 (de) 2004-09-15
DE69433981D1 (de) 2004-10-07
CN1139375A (zh) 1997-01-01
AU1092495A (en) 1995-06-06
EP0729324A1 (en) 1996-09-04
EP0729324A4 (en) 1997-09-03
US5824072A (en) 1998-10-20
TW368411B (en) 1999-09-01
US5443505A (en) 1995-08-22
JPH09505300A (ja) 1997-05-27
US5766242A (en) 1998-06-16
DE69433981T2 (de) 2005-09-01
WO1995013765A1 (en) 1995-05-26
EP0729324B1 (en) 2004-09-01

Similar Documents

Publication Publication Date Title
KR960705512A (ko) 생체적합성 안과용 삽입체(biocompatible ocular implants)
Amid et al. Local anesthesia for inguinal hernia repair step-by-step procedure.
DK0669128T3 (da) Sustained-release mikrosfære indeholdende antipsykotikum og fremgangsmåde til at fremstille samme
AU4319699A (en) Antimicrobial locks comprising taurinamide derivatives and carboxylic acids and/or salts thereof
ATE112677T1 (de) Augeneinlage.
DE69113470D1 (de) Intraokulares und intraorbitales Implantat zur kontrollierten Zuführung von Arzneimitteln.
AU576365B2 (en) Collagen and or fibrinogen as carrier of drugs for their introduction into cellular lesion areas
CA2368335A1 (en) Inflatable device and method for treating glaucoma
SE8803087L (sv) Ett nytt saett foer behandling av erektil dysfunktion
ATE284179T1 (de) Implantierbare vorrichtung zur kontrollierten abgabe von arzneimitteln unmittelbar an einen inneren teil des körpers
DE10299034I2 (de) Formulierung zur topischen Anwendung am Auge, die Olopatadine enthalten, zur Behandlung von allergischen Augenerkrankungen.
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
AU3080392A (en) Sol-controlled gelatine-based thermocolloidal matrix for peroral prolonged action administration forms
DE68918099D1 (de) Pharmazeutische behandlung einer augenentwicklung.
ATE282406T1 (de) Arzneimittel und verfahren zur behandlung von intrazellulären infektionen
RU94002133A (ru) 6-хлор-5-фтор-3-(2-теноил)-2-оксиндол-1-карбоксамид как аналгезирующее и противовоспалительное средство
DE69105349D1 (de) Behandlung von intraocularem Druck mit einer synergistischen Kombination zur ophthalmischen Verwendung.
DE69106777D1 (de) Behandlung von intraokularem Druck mit einer ophthalmischen synergistischen Kombination.
EP0799618A3 (en) Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and teatment of cancer
DE69100171T2 (de) Synergistische Kombination zur ophthalmischen Verwendung.
DE69524388D1 (de) 4-amino-6-substituierte mycophenolsäurederivate mit immunsuppressiver wirkung
Gupta Efficacy of miconazole in experimental keratomycosis
CA2176145A1 (en) Biocompatible ocular implants
RU96113117A (ru) Биосовместимые глазные имплантанты
RU99100578A (ru) Способ лечения глазных болезней

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
NORF Unpaid initial registration fee